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The unexpected finding that autologous induced pluripotent stem cell (iPSC)-derived teratomas are immuno-
genic in syngeneic hosts sparked pessimism over their therapeutic potential; however, two recent reports
(Guha et al., 2013 and Araki et al., 2013; the latter in this issue of Cell Stem Cell) contradict previous findings,
showing no immunogenicity of in vitro differentiated syngeneic iPS-derived cells and supporting their safety.The possibility of using autologous iPSCs
in a therapeutic setting has been met with
a high degree of caution due to previous
findings reporting the potential of iPSC-
derived teratomas to elicit an immune
response in syngeneic hosts. However,
two recent reports in favor of their safety
have now shifted the debate to a more
optimistic outlook. The debate started
from a report that revealed unexpected
immune responses to teratomas, tumors
containing differentiated cells of all three
germ layers that were derived from synge-
neic murine iPSCs (Zhao et al., 2011). It
had been believed that syngeneic ‘‘self’’-
iPSCs and their progeny would not cause
any immune response in the host due
to self-tolerance, a central dogma of
immunology. The study by Zhao and
colleagues, however, cautioned against
such an optimistic view by showing
abnormal protein expression, T cell infil-
tration, and immune rejection of the tera-
tomas. In our view, the media reacted
too quickly to these findings and reported
them from an unnecessarily pessimistic
point of view, casting doubt on the usage
of iPSCs in regenerative medicine. Fortu-
nately, the stem cell research community
pleaded for patience because the report
left many unanswered questions. Most
notably, it remained to be determined
whether immune responses could be eli-
cited by differentiated tissues derived
from syngeneic iPSCs, especially from
those made using integration-free ap-
proaches (Yamanaka, 2012; Okano
et al., 2013). In this issue of Cell Stem
Cell, Boyd and colleagues addressed
the question of immunogenicity by using
in vitro differentiated cells derived from
syngeneic iPSCs that represented eachgerm layer (Guha et al., 2013). This report,
in combination with a recent report by Abe
and colleagues (Araki et al., 2013), has
shifted the balance regarding immunoge-
nicity of syngeneic iPSCs in favor of their
ability to engender self-tolerance.
Guha et al. first generated terminally
differentiated endothelial cells, hepato-
cytes, and neuronal cells from ESCs and
iPSCs in vitro. They then tested the immu-
nogenicity of those cells in vitro and in vivo
by measuring T cell responses in cocul-
ture and tissue engraftment, respectively,
in a transplantation setting. In the initial
characterization, some types of differenti-
ated cells were found to express MHC
class I and costimulatory molecules that
would enable them to induce T cell re-
sponses to antigenic peptides (i.e.,
nonself peptides or tumor-associated
peptides) if they were presented on
MHC class I of the cell surface. However,
coculture experiments revealed a lack of
T cell response to undifferentiated synge-
neic iPSCs or their differentiated proge-
nies. To further assess the potential for
immunogenicity in a more clinically rele-
vant setting, they transplanted the three
types of in vitro differentiated cells into
syngeneic mice. Consistent with the
in vitro result, lack of T cell infiltration
was confirmed by histology and immuno-
histochemistry of transplanted tissue, and
no immunological memory to syngeneic
tissue was established in peripheral
T cells of transplanted mice. In contrast,
allogeneic tissues immediately induced
severe immune reactions both in vitro
and in vivo. These findings suggest that
no immunogenic protein was produced,
at least in iPSC-derived endothelial cells,
hepatocytes, and neuronal cells.Cell Stem CeAraki et al. (2013) took a similar
approach, but focused their comparison
on the immunogenicity of iPSCs com-
pared to ESCs. Like Guha et al. (2013),
they found no evidence of immune rejec-
tion upon transplantation of iPSC- or
ESC-derived tissues. For their transplan-
tation studies, however, Araki et al.
(2013) used skin grafts and bone marrow
from chimeric iPSC- or ESC-derived
mice rather than that from cells that
were generated from pluripotent cells
through directed differentiation in vitro.
Although both papers come to the same
conclusion, one can imagine that the
differences in cell sources could have
clinical implications, because in vitro
derived cells represent a promising
source of therapeutically useful cells.
A controversial aspect of all three re-
ports relates to aberrant expression of a
specific set of genes that were initially
implicated in the immune rejection of
iPSC-derived teratomas. Zhao et al.
(2011) showed a significantly higher rejec-
tion rate of iPSC-derived teratomas
than ESC-derived teratomas, which was
linked to overexpression of tumor-related
genes, includingHormad and Zg16, in ter-
atomas derived from syngeneic iPSCs.
They also showed that these tumor-asso-
ciated antigens induced cytokine re-
sponses by T cells. However, by using
multiple pluripotent stem cell lines, Araki
et al. (2013) showed negligible immune
reaction to teratomas derived from syn-
geneic iPSCs and syngeneic ESCs.
Moreover, they observed no significant
elevation of Hormad and Zg16 in either
teratoma or dermal cells. In addition,
they confirmed indistinguishable expres-
sion profiles between tissue panels ofll 12, April 4, 2013 ª2013 Elsevier Inc. 385
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Previewsadult mice generated by tetraploid
complementation of ESCs and iPSCs.
Guha et al. also demonstrated syngeneic
teratoma formation in 100% of trans-
planted recipients regardless of whether
ESCs or iPSCs were used and no differ-
ences in expression of Hormad, Zg16,
and Retn genes in teratomas of both
origins.
These differences may be attributable
to different iPSC lines used in the different
studies because vector choices for re-
programming may affect immunogenicity
(Okita et al., 2011a). Zhao et al. (2011)
used iPSCs derived with retroviruses or
integration-free episomal plasmids. In
contrast, Araki et al. (2013) only used
plasmid-derived iPSCs, and Guha et al.
(2013) used both plasmids and lentivi-
ruses for generating iPSCs. Retroviral
vectors prefer to be integrated in tran-
scriptionally active sites, and occasionally
cause continuous leakage of transgenes
or activation of neighbor genes around
integration sites that correlate to aberrant
production of an immunogenic protein,
including Oct4 (Dhodapkar et al., 2010).
In keeping with this notion, Zhao et al.
reported strong rejections only with retro-
virally derived iPSCs, but not with integra-
tion free-iPSCs. The lentiviral vectors
used by Guha et al. are thought to have
less chances of such aberrant transgene
expression (Montini et al., 2006). These
data suggest that in generating iPSCs
for transplantation therapies, retroviruses
should not be used in order to avoid
vector-driven genotoxicity, including
immunogenicity.386 Cell Stem Cell 12, April 4, 2013 ª2013 ElEven with the two current comprehen-
sive studies, we should not be overly
optimistic about the potential for immuno-
genicity of iPSCs. Primate and human
iPSCs have not been tested for their
immunological activities. In addition,
each type of mature cell expresses a
different set of genes and proteins; there-
fore, it will be necessary to carefully
screen each cell type used in clinical ap-
plications for potential immunogenicity.
Considering the cost and time required
to generate iPSC lines from each patient
in good manufacturing protocol (GMP)
facilities, several groups in the world are
now trying to initiate banking of clinical-
grade iPSC lines from HLA homologous
donors (Okita et al., 2011b, Taylor et al.,
2012). In our own efforts at the Center for
iPS Cell Research and Application (CiRA,
Kyoto University), we aim to generate an
iPSC bank that would cover 90% of
Japanese such that each covered indi-
vidual would have a match with at least
one HLA haploidentical iPSC line within
the next decade. Needless to say, one
important aim of the project is to clarify
the immunological impact of HLA match-
ing for allogeneic cell transplantation. In
such an HLA-matched but minor antigen
mismatched allogeneic transplantation
setting, it will be extremely important to
carefully select less immunogenic iPSC
clones and differentiated cells and to
continuously monitor and control un-
wanted immunological responses after
transplantation. The recent findings by
Guha et al. and Araki et al. mark a step
forward in reaching this goal.sevier Inc.ACKNOWLEDGMENTS
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